FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016339369> ?p ?o ?g. }

• W2016339369 endingPage "317" @default.
• W2016339369 startingPage "307" @default.
• W2016339369 abstract "To assess the effects of a growth hormone (GH) replacement therapy using a GH dose regimen based on serum insulin-like growth factor (IGF-I) concentrations in Japanese adults with GH deficiency (GHD). In this multicentre, uncontrolled, open-label study, Japanese adults with GHD who had received either GH replacement therapy (GH–GH group, n = 35) or placebo (Placebo–GH group, n = 36) in a previous randomised, double-blind, placebo-controlled trial were treated with GH replacement therapy for 48 weeks. GH treatment was started at a dose of 0.003 mg/kg/day administered by subcutaneous injection for the first 8 weeks, after which the dose was adjusted to maintain patients’ serum IGF-I levels within the reference range adjusted for age and gender. Body composition, serum lipids, serum IGF-I and IGF binding protein-3 (IGFBP-3) levels were measured throughout study. Symptom and quality of life scores were also determined. Lean body mass (LBM) was increased compared with baseline (the end of the preceding double-blind trial) at 24 and 48 weeks, with a mean (±SD) increase of 1.3% (±4.2%) at week 48 in the GH–GH group (an increase of 6.6% [±6.0%] from the start of the preceding double-blind trial) and a larger increase of 4.7% (±5.9%) in the Placebo–GH group. Body fat mass (BFM) increased slightly from baseline in the GH–GH group with a mean increase of 2.9 ± 10.6% at week 48 (a decrease from the start of the preceding double-blind trial at 48 weeks of 7.8% [±15.0%]) but decreased by 6.5% (±11.7%) at week 48 in the Placebo–GH group. Serum lipids were unchanged or slightly increased from baseline in the GH–GH group but patients’ lipid profiles improved in the Placebo–GH group. In patients who received placebo during the double-blind study, individualised GH therapy in this open-label study increased mean LBM at 48 weeks by 6.2 ± 6.8% in patients with CO GHD and by 3.0 ± 4.4% in patients with AO GHD. Changes in mean LBM and mean BFM at week 48 were +4.1 ± 4.5% and −2.4 ± 10.5%, respectively, in females and +5.0 ± 6.7% and −8.9 ± 11.8%, respectively, in males. In patients who received GH treatment during the double-blind study, overall changes in LBM, BFM and IGF-I SD score after 24 weeks and 48 weeks were small, with no significant differences between subgroups. While the overall incidence of adverse events was broadly similar in the GH–GH and Placebo–GH groups (97% and 89%, respectively), the incidence of treatment-related events was higher in the GH–GH group (83% vs 42% in the Placebo–GH group). Most adverse events in both treatment groups were of mild or moderate severity and not clinically significant. The incidences of oedema and cases of high IGF-I during the IGF-I level-adjusted treatment regimen were lower than those during the preceding fixed dose titration. Long-term GH replacement therapy was well tolerated in Japanese adults with GHD. GH treatment maintained the improvements in body composition and lipid profiles in the patients previously treated in the double-blind study (GH–GH group) and improved these parameters in previously untreated patients (Placebo–GH group). Individualised GH administration based on IGF-I levels was well-tolerated and effective." @default.
• W2016339369 created "2016-06-24" @default.
• W2016339369 creator A5015016528 @default.
• W2016339369 creator A5021226292 @default.
• W2016339369 creator A5044760409 @default.
• W2016339369 creator A5048027547 @default.
• W2016339369 creator A5049262522 @default.
• W2016339369 creator A5049772836 @default.
• W2016339369 creator A5091861346 @default.
• W2016339369 date "2008-08-01" @default.
• W2016339369 modified "2023-09-28" @default.
• W2016339369 title "Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD)" @default.
• W2016339369 cites W2000571801 @default.
• W2016339369 cites W2009517655 @default.
• W2016339369 cites W2019582539 @default.
• W2016339369 cites W2032028894 @default.
• W2016339369 cites W2036286877 @default.
• W2016339369 cites W2075084544 @default.
• W2016339369 cites W2076726014 @default.
• W2016339369 cites W2081600359 @default.
• W2016339369 cites W2084090215 @default.
• W2016339369 cites W2095562369 @default.
• W2016339369 cites W2098547168 @default.
• W2016339369 cites W2111843196 @default.
• W2016339369 cites W2112250110 @default.
• W2016339369 cites W2126723117 @default.
• W2016339369 cites W2155658977 @default.
• W2016339369 cites W2159817497 @default.
• W2016339369 cites W2185068816 @default.
• W2016339369 cites W2606513528 @default.
• W2016339369 cites W4229962053 @default.
• W2016339369 cites W4230422193 @default.
• W2016339369 cites W4232243161 @default.
• W2016339369 cites W4234150232 @default.
• W2016339369 cites W4237952443 @default.
• W2016339369 cites W4238620164 @default.
• W2016339369 cites W4245998196 @default.
• W2016339369 cites W4246301913 @default.
• W2016339369 cites W4250556552 @default.
• W2016339369 cites W4251718080 @default.
• W2016339369 cites W4253356275 @default.
• W2016339369 cites W4255532836 @default.
• W2016339369 cites W4256141595 @default.
• W2016339369 doi "https://doi.org/10.1016/j.ghir.2007.12.001" @default.
• W2016339369 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18282776" @default.
• W2016339369 hasPublicationYear "2008" @default.
• W2016339369 type Work @default.
• W2016339369 sameAs 2016339369 @default.
• W2016339369 citedByCount "15" @default.
• W2016339369 countsByYear W20163393692012 @default.
• W2016339369 countsByYear W20163393692013 @default.
• W2016339369 countsByYear W20163393692014 @default.
• W2016339369 countsByYear W20163393692015 @default.
• W2016339369 countsByYear W20163393692016 @default.
• W2016339369 countsByYear W20163393692017 @default.
• W2016339369 countsByYear W20163393692018 @default.
• W2016339369 countsByYear W20163393692020 @default.
• W2016339369 countsByYear W20163393692021 @default.
• W2016339369 crossrefType "journal-article" @default.
• W2016339369 hasAuthorship W2016339369A5015016528 @default.
• W2016339369 hasAuthorship W2016339369A5021226292 @default.
• W2016339369 hasAuthorship W2016339369A5044760409 @default.
• W2016339369 hasAuthorship W2016339369A5048027547 @default.
• W2016339369 hasAuthorship W2016339369A5049262522 @default.
• W2016339369 hasAuthorship W2016339369A5049772836 @default.
• W2016339369 hasAuthorship W2016339369A5091861346 @default.
• W2016339369 hasConcept C113675107 @default.
• W2016339369 hasConcept C120863210 @default.
• W2016339369 hasConcept C126322002 @default.
• W2016339369 hasConcept C134018914 @default.
• W2016339369 hasConcept C142724271 @default.
• W2016339369 hasConcept C147583825 @default.
• W2016339369 hasConcept C204787440 @default.
• W2016339369 hasConcept C27081682 @default.
• W2016339369 hasConcept C2778328710 @default.
• W2016339369 hasConcept C2779952775 @default.
• W2016339369 hasConcept C2781413609 @default.
• W2016339369 hasConcept C2984496839 @default.
• W2016339369 hasConcept C71315377 @default.
• W2016339369 hasConcept C71924100 @default.
• W2016339369 hasConceptScore W2016339369C113675107 @default.
• W2016339369 hasConceptScore W2016339369C120863210 @default.
• W2016339369 hasConceptScore W2016339369C126322002 @default.
• W2016339369 hasConceptScore W2016339369C134018914 @default.
• W2016339369 hasConceptScore W2016339369C142724271 @default.
• W2016339369 hasConceptScore W2016339369C147583825 @default.
• W2016339369 hasConceptScore W2016339369C204787440 @default.
• W2016339369 hasConceptScore W2016339369C27081682 @default.
• W2016339369 hasConceptScore W2016339369C2778328710 @default.
• W2016339369 hasConceptScore W2016339369C2779952775 @default.
• W2016339369 hasConceptScore W2016339369C2781413609 @default.
• W2016339369 hasConceptScore W2016339369C2984496839 @default.
• W2016339369 hasConceptScore W2016339369C71315377 @default.
• W2016339369 hasConceptScore W2016339369C71924100 @default.
• W2016339369 hasIssue "4" @default.
• W2016339369 hasLocation W20163393691 @default.
• W2016339369 hasLocation W20163393692 @default.
• W2016339369 hasOpenAccess W2016339369 @default.

• next